Ulcerative colitis: ABTECT – Maintenance therapy

by Pauline Lauterbach | Jan 26, 2026 | Active, recruitment completed, For study partners

Ulcerative colitis: ABTECT – Maintenance therapy ClinicalTrials.gov ID: NCT05535946Sponsor: Abivax S.A. Information provided by: Abivax S.A. (responsible party) Official title:A randomized, double-blind, multicenter Phase III study to evaluate the long-term efficacy...

Crohn’s disease: FORTIFY study (Risankizumab)

by Pauline Lauterbach | Jan 19, 2026 | For participants, Ongoing

Crohn’s disease: FORTIFY study (Risankizumab) This comprehensive study includes several sub-studies to evaluate various aspects of Risankizumab treatment, including maintenance therapy, long-term safety, and patient-reported outcomes. Open-label extensions...

Crohn’s disease: GRAVITI study (Guselkumab as subcutaneous therapy)

by Pauline Lauterbach | Jan 19, 2026 | For participants, Ongoing

Crohn’s disease: GRAVITI study (Guselkumab as subcutaneous therapy) This study examines the safety and efficacy of guselkumab as a subcutaneous (injected under the skin) therapy for people with Crohn’s...

Crohn’s disease: DUET-CD study (combination of guselkumab and golimumab)

by Pauline Lauterbach | Jan 19, 2026 | For participants, Ongoing

Crohn’s disease: DUET-CD study (combination of guselkumab and golimumab) Similar to ulcerative colitis, this study tests the combination of the two drugs for Crohn’s disease and compares it with the single application. The aim is to determine which therapy...

Ulcerative colitis: DUET-UC study (combination of guselkumab and golimumab)

by Pauline Lauterbach | Jan 19, 2026 | For participants, Ongoing

Ulcerative colitis: DUET-UC study (combination of guselkumab and golimumab) This study examines the efficacy and safety of combining the two medications guselkumab and golimumab compared to using each medication individually. The study is aimed at patients with...